Overview of metastatic disease of the central nervous system

Area of Science:

• Oncology
• Neuro-oncology
• Cancer Therapeutics

Background:

• Cancer diagnoses are rising globally, projected to reach 22 million worldwide by 2030.
• Advances in cancer therapies, including targeted therapies and immunotherapies, have significantly improved patient survival.
• Increased patient survival leads to a higher incidence of central nervous system (CNS) metastases.

Purpose of the Study:

• To highlight the growing challenge of CNS metastases in cancer patients.
• To discuss the unique biological barriers protecting CNS tumors.
• To underscore the need for novel therapeutic approaches for CNS cancers.

Main Methods:

• Review of current trends in cancer incidence and therapy.
• Analysis of factors contributing to CNS metastasis development.
• Examination of challenges in treating CNS tumors, including the blood-brain barrier and drug resistance.

Main Results:

• Effective systemic cancer therapies prolong survival, increasing the risk of CNS metastases.
• The CNS acts as a sanctuary site due to the blood-brain barrier, tumor microenvironment, and immune privilege.
• CNS metastases often occur late in disease course, with patients frequently experiencing drug resistance.

Conclusions:

• Current systemic therapies may not effectively treat CNS metastases due to limited blood-brain barrier penetration.
• Molecular discordance between systemic and CNS tumors can impact treatment efficacy.
• There is a critical need for innovative treatments to overcome CNS-specific therapeutic challenges.